While the contributions of neuroinflammatory reactive glia to progressive neurodegenerative diseases are not fully understood and are a topic of continuing debate [48–50], our data highlight the potential of rapamycin for protecting against not only the primary neurotoxicity of tauopathy, but also any secondary neuroinflammatory processes activated by tau toxicity that might contribute to bystander neuronal damage. This evidence concerns the gene MAPT and tauopathy.